* Andre, T. et al. (2024). Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. The New England journal of medicine, 391(21), 2014–2026. https://doi.org/10.1056/NEJMoa2402141
Idylla™ CDx MSI Test (A0220/6) is approved in the US under P250005 and is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR). Launch in Europe is planned EO March 2026.